Enzalutamide in Japanese patients with chemotherapy‐naïve, metastatic castration‐resistant prostate cancer: A post‐hoc analysis of the placebo‐controlled PREVAIL trial-Reference-Cited by-同舟云学术

Enzalutamide in Japanese patients with chemotherapy‐naïve, metastatic castration‐resistant prostate cancer: A post‐hoc analysis of the placebo‐controlled PREVAIL trial

Published:2016-03-27 Issue:5 Volume:23 Page:395-403
ISSN:0919-8172
Container-title:International Journal of Urology
language:en
Short-container-title:Int. J. Urol.

Author:

Kimura Go¹,Yonese Junji²,Fukagai Takashi³,Kamba Tomomi⁴,Nishimura Kazuo⁵,Nozawa Masahiro⁶,Mansbach Hank⁷,Theeuwes Ad⁸,Beer Tomasz M⁹,Tombal Bertrand¹⁰,Ueda Takeshi¹¹

Affiliation:

1. Department of Urology Nippon Medical School Tokyo Japan

2. Department of Urology, Cancer Institute Hospital of Japanese Foundation for Cancer Research Tokyo Japan

3. Department of Urology, Showa University Koto Toyosu Hospital Tokyo Japan

4. Department of Urology, Kyoto University Hospital Kyoto Japan

5. Department of Urology, Osaka Medical Center for Cancer and Cardiovascular Diseases Osaka Japan

6. Department of Urology, Kinki University Faculty of Medicine Higashiosaka City Osaka Japan

7. Clinical Development, Medivation San Francisco California USA

8. Biostatistics, Astellas Pharma Global Development Leiden The Netherlands

9. OHSU Knight Cancer Institute Oregon Health and Science University Portland Oregon USA

10. Division of Urology Cliniques Universitaires Saint‐Luc Brussels Belgium

11. Division of Urology, Chiba Cancer Center Chiba Japan

Funder

Astellas Pharma

Publisher

Wiley

Subject

Urology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/iju.13072

Reference29 articles.

1. FerlayJ SoerjomataramI ErikMet al.GLOBOCAN 2012 v1.0 Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 2013. [Cited 31 Apr 2015]. Available from URL:http://globocan.iarc.fr

2. Cancer Incidence and Incidence Rates in Japan in 2007: A Study of 21 Population-based Cancer Registries for the Monitoring of Cancer Incidence in Japan (MCIJ) Project

3. Cancer Information Service National Cancer Center Japan.Cancer mortality from Vital Statistics in Japan (1958–2014). 2015. [Cited 4 May 2015]. Available from URL:http://ganjoho.jp/en/professional/statistics/table_download.html

4. An overview of prostate diseases and their characteristics specific to Asian men

5. Studies on prostatic cancer effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate;Huggins C;Cancer Res.,1941

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Determination of enzalutamide long-term safety and efficacy for castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy: a multicenter prospective DELC study;Japanese Journal of Clinical Oncology;2024-02-01

2. Long-term safety and efficacy of enzalutamide for men with castration-resistant prostate cancer: a multicenter, prospective DELC study;2023-08-30

3. Effects of Drug Interactions between Enzalutamide and Calcium Channel Blockers on Blood Pressure Change;Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences);2023-02-10

4. Androgen receptor axis‑targeted agents are not superior to conventional hormonal therapy for treatment of metastatic prostate cancer;Oncology Letters;2022-08-09

5. Efficacy of New Therapies for Relapse After Docetaxel Treatment of Bone Metastatic Castration-resistant Prostate Cancer in Clinical Practice;Anticancer Research;2022-02-26